Histone variant H3.3 promotes metastasis in alveolar rhabdomyosarcoma.
adhesion
epigenetics
histone variant
metastasis
motility
sarcoma
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
15
12
2022
received:
22
08
2022
accepted:
21
12
2022
pubmed:
28
12
2022
medline:
14
2
2023
entrez:
27
12
2022
Statut:
ppublish
Résumé
The relatively quiet mutational landscape of rhabdomyosarcoma (RMS) suggests that epigenetic deregulation could be central to oncogenesis and tumour aggressiveness. Histone variants have long been recognised as important epigenetic regulators of gene expression. However, the role of histone variants in RMS has not been studied hitherto. In this study, we show that histone variant H3.3 is overexpressed in alveolar RMS (ARMS), an aggressive subtype of RMS. Functionally, knockdown of H3F3A, which encodes for H3.3, significantly impairs the ability of ARMS cells to undertake migration and invasion and reduces Rho activation. In addition, a striking reduction in metastatic tumour burden and improved survival is apparent in vivo. Using RNA-sequencing and ChIP-sequencing analyses, we identified melanoma cell adhesion molecule (MCAM/CD146) as a direct downstream target of H3.3. Loss of H3.3 resulted in a reduction in the presence of active marks and an increase in the occupancy of H1 at the MCAM promoter. Cell migration and invasion were rescued in H3F3A-depleted cells through MCAM overexpression. Moreover, we identified G9a, a lysine methyltransferase encoded by EHMT2, as an upstream regulator of H3F3A. Therefore, this study identifies a novel H3.3 dependent axis involved in ARMS metastasis. These findings establish the potential of MCAM as a therapeutic target for high-risk ARMS patients. © 2022 The Pathological Society of Great Britain and Ireland.
Substances chimiques
EHMT2 protein, human
EC 2.1.1.43
Histocompatibility Antigens
0
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Histones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
342-356Informations de copyright
© 2022 The Pathological Society of Great Britain and Ireland.
Références
Perez EA, Kassira N, Cheung MC, et al. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res 2011; 170: e243-e251.
Martin-Giacalone BA, Weinstein PA, Plon SE, et al. Pediatric rhabdomyosarcoma: epidemiology and genetic susceptibility. J Clin Med 2021; 10: 2028.
Dasgupta R, Fuchs J, Rodeberg D. Rhabdomyosarcoma. Semin Pediatr Surg 2016; 25: 276-283.
Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002; 1: 97-104.
Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol 2013; 20: 387-397.
Seki M, Nishimura R, Yoshida K, et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun 2015; 6: 7557.
Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014; 4: 216-231.
Anderson J, Gordon T, McManus A, et al. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 2001; 85: 831-835.
Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001; 20: 5736-5746.
Epstein JA, Lam P, Jepeal L, et al. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 1995; 270: 11719-11722.
Miller PJ, Hollenbach AD. The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. Biochim Biophys Acta 2007; 1770: 1450-1458.
Xia SJ, Rajput P, Strzelecki DM, et al. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein. Lab Invest 2007; 87: 318-325.
Chen C, Dorado Garcia H, Scheer M, et al. Current and future treatment strategies for rhabdomyosarcoma. Front Oncol 2019; 9: 1458.
Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66: 6936-6946.
Williamson D, Missiaglia E, de Reyniès A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28: 2151-2158.
Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012; 59: 5-10.
Arndt CAS, Bisogno G, Koscielniak E. Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev 2018; 68: 94-101.
Nguyen TH, Barr FG. Therapeutic approaches targeting PAX3-FOXO1 and its regulatory and transcriptional pathways in rhabdomyosarcoma. Molecules 2018; 23: 2798.
Wachtel M, Schäfer BW. PAX3-FOXO1: zooming in on an “undruggable” target. Semin Cancer Biol 2018; 50: 115-123.
Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004; 116: 259-272.
Andrews AJ, Luger K. Nucleosome structure(s) and stability: variations on a theme. Annu Rev Biophys 2011; 40: 99-117.
Cutter AR, Hayes JJ. A brief review of nucleosome structure. FEBS Lett 2015; 589: 2914-2922.
Talbert PB, Henikoff S. Histone variants on the move: substrates for chromatin dynamics. Nat Rev Mol Cell Biol 2017; 18: 115-126.
Hake SB, Allis CD. Histone H3 variants and their potential role in indexing mammalian genomes: the “H3 barcode hypothesis”. Proc Natl Acad Sci U S A 2006; 103: 6428-6435.
Ahmad K, Henikoff S. The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol Cell 2002; 9: 1191-1200.
Wirbelauer C, Bell O, Schübeler D. Variant histone H3.3 is deposited at sites of nucleosomal displacement throughout transcribed genes while active histone modifications show a promoter-proximal bias. Genes Dev 2005; 19: 1761-1766.
Jin C, Zang C, Wei G, et al. H3.3/H2A.Z double variant-containing nucleosomes mark ‘nucleosome-free regions’ of active promoters and other regulatory regions. Nat Genet 2009; 41: 941-945.
Goldberg AD, Banaszynski LA, Noh KM, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010; 140: 678-691.
Chen P, Zhao J, Wang Y, et al. H3.3 actively marks enhancers and primes gene transcription via opening higher-ordered chromatin. Genes Dev 2013; 27: 2109-2124.
Deaton AM, Gómez-Rodríguez M, Mieczkowski J, et al. Enhancer regions show high histone H3.3 turnover that changes during differentiation. Elife 2016; 5: e15316.
Kaludov NK, Pabón-Peña L, Seavy M, et al. A mouse histone H1 variant, H1b, binds preferentially to a regulatory sequence within a mouse H3.2 replication-dependent histone gene. J Biol Chem 1997; 272: 15120-15127.
Braunschweig U, Hogan GJ, Pagie L, et al. Histone H1 binding is inhibited by histone variant H3.3. EMBO J 2009; 28: 3635-3645.
Yang JH, Song Y, Seol JH, et al. Myogenic transcriptional activation of MyoD mediated by replication-independent histone deposition. Proc Natl Acad Sci U S A 2011; 108: 85-90.
Ng RK, Gurdon JB. Epigenetic memory of an active gene state depends on histone H3.3 incorporation into chromatin in the absence of transcription. Nat Cell Biol 2008; 10: 102-109.
Fang HT, El Farran CA, Xing QR, et al. Global H3.3 dynamic deposition defines its bimodal role in cell fate transition. Nat Commun 2018; 9: 1537.
Jang CW, Shibata Y, Starmer J, et al. Histone H3.3 maintains genome integrity during mammalian development. Genes Dev 2015; 29: 1377-1392.
Park J, Lee H, Han N, et al. Long non-coding RNA ChRO1 facilitates ATRX/DAXX-dependent H3.3 deposition for transcription-associated heterochromatin reorganization. Nucleic Acids Res 2018; 46: 11759-11775.
Ray-Gallet D, Quivy JP, Scamps C, et al. HIRA is critical for a nucleosome assembly pathway independent of DNA synthesis. Mol Cell 2002; 9: 1091-1100.
Ray-Gallet D, Ricketts MD, Sato Y, et al. Functional activity of the H3.3 histone chaperone complex HIRA requires trimerization of the HIRA subunit. Nat Commun 2018; 9: 3103.
Szenker E, Lacoste N, Almouzni G. A developmental requirement for HIRA-dependent H3.3 deposition revealed at gastrulation in Xenopus. Cell Rep 2012; 1: 730-740.
Adam S, Polo SE, Almouzni G. Transcription recovery after DNA damage requires chromatin priming by the H3.3 histone chaperone HIRA. Cell 2013; 155: 94-106.
Zhang H, Gan H, Wang Z, et al. RPA interacts with HIRA and regulates H3.3 deposition at gene regulatory elements in mammalian cells. Mol Cell 2017; 65: 272-284.
Xiong C, Wen Z, Yu J, et al. UBN1/2 of HIRA complex is responsible for recognition and deposition of H3.3 at cis-regulatory elements of genes in mouse ES cells. BMC Biol 2018; 16: 110.
Drané P, Ouararhni K, Depaux A, et al. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 2010; 24: 1253-1265.
Lewis PW, Elsaesser SJ, Noh KM, et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A 2010; 107: 14075-14080.
Elsässer SJ, Huang H, Lewis PW, et al. DAXX envelops a histone H3.3-H4 dimer for H3.3-specific recognition. Nature 2012; 491: 560-565.
Hoelper D, Huang H, Jain AY, et al. Structural and mechanistic insights into ATRX-dependent and -independent functions of the histone chaperone DAXX. Nat Commun 2017; 8: 1193.
Park SM, Choi EY, Bae M, et al. Histone variant H3F3A promotes lung cancer cell migration through intronic regulation. Nat Commun 2016; 7: 12914.
Gomes AP, Ilter D, Low V, et al. Dynamic incorporation of histone H3 variants into chromatin is essential for acquisition of aggressive traits and metastatic colonization. Cancer Cell 2019; 36: 402-417.e13.
Huang X, Liu J, Ma Q. Prohibitin participates in the HIRA complex to promote cell metastasis in breast cancer cell lines. FEBS Open Bio 2020; 10: 2182-2190.
Ueda H, Akiyama Y, Shimada S, et al. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs. Endocr Relat Cancer 2018; 25: 619-631.
Bhat AV, Palanichamy Kala M, Rao VK, et al. Epigenetic regulation of the PTEN-AKT-RAC1 axis by G9a is critical for tumor growth in alveolar rhabdomyosarcoma. Cancer Res 2019; 79: 2232-2243.
Wu Z, Wu Z, Li J, et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour Biol 2012; 33: 1619-1628.
Wang Z, Xu Q, Zhang N, et al. CD146, from a melanoma cell adhesion molecule to a signaling receptor. Signal Transduct Target Ther 2020; 5: 148.
Pal A, Chiu HY, Taneja R. Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: emerging targets and therapeutics. Redox Biol 2019; 25: 101124.
Zeng P, Li H, Lu PH, et al. Prognostic value of CD146 in solid tumor: a systematic review and meta-analysis. Sci Rep 2017; 7: 4223.
Orentas RJ, Yang JJ, Wen X, et al. Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol 2012; 2: 194.
Sobral LM, Sechler M, Parrish JK, et al. KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma. Genes Cancer 2020; 11: 53-65.
Mills L, Tellez C, Huang S, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002; 62: 5106-5114.
McGary EC, Heimberger A, Mills L, et al. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res 2003; 9: 6560-6566.
Stalin J, Nollet M, Dignat-George F, et al. Therapeutic and diagnostic antibodies to CD146: thirty years of research on its potential for detection and treatment of tumors. Antibodies (Basel) 2017; 6: 17.
Nollet M, Stalin J, Moyon A, et al. A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule. Oncotarget 2017; 8: 112283-112296.
Stalin J, Traboulsi W, Vivancos-Stalin L, et al. Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors. Int J Cancer 2020; 147: 1666-1679.
Lian X, Bond JS, Bharathy N, et al. Defining the extracellular matrix of rhabdomyosarcoma. Front Oncol 2021; 11: 601957.
Liu J, Shen JX, Wu HT, et al. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target. Discov Med 2018; 25: 211-223.
Zhang Z, Wang Y, Zhang J, et al. COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway. Mol Med Rep 2018; 17: 5037-5042.
Ma HP, Chang HL, Bamodu OA, et al. Collagen 1A1 (COL1A1) is a reliable biomarker and putative therapeutic target for hepatocellular carcinogenesis and metastasis. Cancers (Basel) 2019; 11: 786.
Hou L, Lin T, Wang Y, et al. Collagen type 1 alpha 1 chain is a novel predictive biomarker of poor progression-free survival and chemoresistance in metastatic lung cancer. J Cancer 2021; 12: 5723-5731.
Li M, Wang J, Wang C, et al. Microenvironment remodeled by tumor and stromal cells elevates fibroblast-derived COL1A1 and facilitates ovarian cancer metastasis. Exp Cell Res 2020; 394: 112153.
Owusu-Ansah KG, Song G, Chen R, et al. COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer. Int J Oncol 2019; 55: 391-404.
Brackenbury WJ. Voltage-gated sodium channels and metastatic disease. Channels (Austin) 2012; 6: 352-361.
Casciello F, Windloch K, Gannon F, et al. Functional role of G9a histone methyltransferase in cancer. Front Immunol 2015; 6: 487.